|
|
||||||||
The George Washington University, Washington, DC
National Institute on Deafness and Other Communication Disorders, Bethesda, MD
National Institute of Neurological Disorders and Stroke, Bethesda, MD
National Institute on Deafness and Other Communication Disorders, Bethesda, MD
Contact author: Allen R. Braun, Language Section, Voice, Speech and Language Branch, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Building 10, Room 8S235A, 10 Center Drive, Bethesda, MD 20892. E-mail: brauna{at}nidcd.nih.gov
Speech-related changes in regional cerebral blood flow (rCBF) were measured using H215O positron-emission tomography in 9 adults with adductor spasmodic dysphonia (ADSD) before and after botulinum toxin (BTX) injection and 10 age- and gender-matched volunteers without neurological disorders. Scans were acquired at rest and during production of continuous narrative speech and whispered speech. Speech was recorded during scan acquisition for offline quantification of voice breaks, pitch breaks, and percentage aperiodicity to assess correlations between treatment-related changes in rCBF and clinical improvement. Results demonstrated that speech-related responses in heteromodal sensory areas were significantly reduced in persons with ADSD, compared with volunteers, before the administration of BTX. Three to 4 weeks after BTX injection, speech-related responses were significantly augmented in these regions and in left hemisphere motor areas commonly associated with oral-laryngeal motor control. This pattern of responses was most strongly correlated with the objective measures of clinical improvement (decreases in the frequency of voice breaks, pitch breaks, and percentage aperiodicity). These data suggest a pathophysiological model for ADSD in which BTX treatment results in more efficient cortical processing of sensory information, making this information available to motor areas that use it to more effectively regulate laryngeal movements.
KEY WORDS: adductor spasmodic dysphonia, botulinum toxin, CNS, rCBF, PET
This article has been cited by other articles:
![]() |
K. Simonyan, F. Tovar-Moll, J. Ostuni, M. Hallett, V. F. Kalasinsky, M. R. Lewin-Smith, E. J. Rushing, A. O. Vortmeyer, and C. L. Ludlow Focal white matter changes in spasmodic dysphonia: a combined diffusion tensor imaging and neuropathological study Brain, February 1, 2008; 131(2): 447 - 459. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASHA Journals | AJA | AJSLP | JSLHR | LSHSS |